EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

Vaginal miR-210-3p as a potential biomarker for pregnancies complicated by early fetal growth restriction: A proof-of-concept case-control study

Elisabetta Bigagli, Elisa Spataro, Lucia Pasquini, Lorenzo Cinci, Mario D'Ambrosio, Chiara De Blasi, Chiara Bartolini, Felice Petraglia, Cristina Luceri

Placenta · 2025

DOI: 10.1016/j.placenta.2025.02.015 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Placenta, 2025. Verfasst von Elisabetta Bigagli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, …. Hauptthemen laut MEDLINE: Fetal Growth Retardation, MicroRNAs, Vagina. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Florence.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Fetal growth restriction (FGR) is associated with increased risk of neonatal morbidity and mortality or long-term adverse outcomes. We investigated the ability of hypoxia and angiogenesis-related miR-210-3p and miR-126-5p to identify early FGR cases and their correlations with neonatal outcomes. METHODS: Twenty-nine women with pregnancies complicated by early FGR diagnosis and 25 controls matched for gestational age (GA) were enrolled and their vaginal fluid (VF) and plasma were collected. MiR-210-3p and miR-126-5p were measured by RT-qPCR and their targets were identified by in-silico analysis limited only to those already experimentally validated in other contexts. RESULTS: Overall, VF levels of miR-210-3p were lower in early FGR cases compared to controls (p < 0.05). miR-210-3p was lower in severe cases and in women who later developed preeclampsia (p < 0.05). VF miR-210-3p levels correlated with lower birth weight, premature birth and severe complications at birth (p < 0.05). miR-210-3p was not detected in plasma and no correlations were observed between miR-126-5p and FGR or neonatal outcomes. In silico analyses identified HIF-1α, HIF-3α, BDNF, IGFBP3, RAD52 and TWIST-1 as experimentally validated targets of miR-210-3p. Among the predicted biological pathways controlled by miR-210-3p, we found hypoxia-responsive signaling such as autophagy, oxidative stress and metabolic pathways. DISCUSSION: Although validation is needed, these findings suggest that VF levels of miR-210-3p may potentially serve as biomarker for the diagnosis of early FGR; future mechanistic studies are also advisable to investigate whether pharmacological strategies based on miR-210-3p, or its downstream targets may be useful for FGR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fetal Growth RetardationMicroRNAsVaginaHumansFemalePregnancyAdultCase-Control StudiesBiomarkersProof of Concept StudyInfant, Newborn

Stichwörter der Autor:innen

BiomarkersFetal growth restrictionPreeclampsiaPregnancyVaginal fluidmiR-210-3p

Substanzen

MicroRNAsMIRN210 microRNA, humanBiomarkers

Autor:innen und Institutionen

  • Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy. Electronic address: elisabetta.bigagli@unifi.it.
  • Department of Experimental and Clinical Biomedical Sciences, Obstetrics and Gynecology, University of Florence, Florence, Italy; Obstetrics and Gynecology, Department of Maternal and Child Health, University of Florence…
  • Fetal Medicine Unit, Department for Woman and Child Health, Careggi University Hospital, Florence, Italy.
  • Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.
  • Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy. Electronic address: cristina.luceri@unifi.it.

Förderung

  • University of Florence

Zitieren

APA

Bigagli, E., Spataro, E., Pasquini, L., Cinci, L., D'Ambrosio, M., De Blasi, C., Bartolini, C., Petraglia, F., & Luceri, C. (2025). Vaginal miR-210-3p as a potential biomarker for pregnancies complicated by early fetal growth restriction: A proof-of-concept case-control study. Placenta. https://doi.org/10.1016/j.placenta.2025.02.015

Vancouver

Bigagli E, Spataro E, Pasquini L, Cinci L, D'Ambrosio M, De Blasi C, et al. Vaginal miR-210-3p as a potential biomarker for pregnancies complicated by early fetal growth restriction: A proof-of-concept case-control study. Placenta. 2025. doi:10.1016/j.placenta.2025.02.015

BibTeX
@article{Bigagli2025,
  author = {Bigagli, Elisabetta and Spataro, Elisa and Pasquini, Lucia and Cinci, Lorenzo and D'Ambrosio, Mario and De Blasi, Chiara and Bartolini, Chiara and Petraglia, Felice and Luceri, Cristina},
  title = {Vaginal miR-210-3p as a potential biomarker for pregnancies complicated by early fetal growth restriction: A proof-of-concept case-control study},
  journal = {Placenta},
  year = {2025},
  doi = {10.1016/j.placenta.2025.02.015}
}
Kostenlos starten →